![](https://cdn.prod.website-files.com/63da4ae4359b4b2bffd2a3b6/6453da50b37b0cf2335f4195_article-hero.jpg)
Related articles
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/6682d322ae6dc1868b33e1f0_large-057-2405-Case%20study%20for%20eCOA_%20adherence_web%20image.jpg)
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/645acebd4c26031990557a26_ben-kolde-t9DooibgMEk-unsplash.jpg)
Medable platform delivers >90% eCOA adherence and scalability
A top-10 American pharmaceutical company came to Medable looking to conduct an extensive weight management master protocol clinical trial with multiple sub-studies across 70+ research sites. The client was concerned about the participant experience, as the trial required participants to enroll through the master protocol before enrolling into a sub-study. Additionally, they wanted to reuse and scale the solution for future trials without compromising the site and patient experience.
Learn how Medable was able to accomplish this and more.
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/65ce0dc2929e7e1c64007c38_SCOPE%202024.jpg)
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/64482e8f985430a5be0f547f_medable-man-reclining-reading-ipad-article-patient-centricity.jpg)
Evidence generation evolved
The pharmaceutical industry faces a daunting challenge: it takes an average of 12 years and $3 billion to bring a new drug to patients, with the FDA approving an average of 50 new therapies yearly.
This pace is inadequate to address humanity's needs and our own future goal of helping the industry produce ten times the number of treatments it does today.
A significant bottleneck is the lengthy clinical trial process, where Phase 3 studies alone can span three years or more. However, a critical factor compounding these timelines is the difficulty in recruiting sufficient patients for these crucial studies, often adding up to 2 years to the already protracted journey.
![Participant in a diabetic polyneuropathy trial](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/6645eb608b920ab5f657f779_PatientCaregiver_011_Web.jpg)
![](https://cdn.prod.website-files.com/63f6c0d2675ee198a17d310a/645acebd4c26031990557a26_ben-kolde-t9DooibgMEk-unsplash.jpg)
Use case: How a top-10 pharma digitized and standardized participant pain body maps
A top-10 pharmaceutical company was looking to standardize the conduct of their diabetic polyneuropathy trials for future use.
Specifically, the client was looking to digitize their paper “body map” forms. These are used by participants to indicate the severity of pain on their bodies.
Traditionally administered on paper, body map assessments had been a source of potential inefficiencies and errors.
The client’s goal was to co-create and own their body maps, while simplifying and streamlining the process for future trials.